Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment options, nucleoside analogues such as decitabine and azacitidine integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation and related downstream therapeutic benefits.
Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. It was first marketed under the name Dacogen®. It is also available as an oral combination product together with the cytidine deaminase inhibitor cedazuridine.
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored as belonging to the intermediate-1, intermediate-2, or high-risk group in the International Prognostic Scoring System.
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
UZ Brussel, Brussels, Belgium
UF Health Shands Hospital, Gainesville, Florida, United States
M D Anderson Cancer Center, Houston, Texas, United States
University Medical Center Groningen (UMCG), Groningen, Netherlands
University of Liège, Liège, Belgium
Radboud university medical center, Nijmegen, Netherlands
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Hôpital Avicenne, Bobigny, France
CHU La Réunion - Site nord, Saint-Denis, La Réunion, France
Chu Amiens, Amiens, France
Johns Hopkins University /ID# 129699, Baltimore, Maryland, United States
Northwestern University Feinberg School of Medicine /ID# 128741, Chicago, Illinois, United States
Dana-Farber Cancer Institute /ID# 127857, Boston, Massachusetts, United States
Temple BMT Program at Jeanes Hospital, Philadelphia, Pennsylvania, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.